A new multi-institution study spearheaded by researchers at Florida State University and the University of California, Los Angeles suggests a tiny protein could play a major role in combating heart failure related to Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder among children.
In collaboration with scientists from across the nation, FSU researchers found that increased levels of the protein sarcospan improve cardiac function by reinforcing cardiac cell membranes, which become feeble in patients with DMD.
Their findings were published in the journal JCI Insight.
The condition, which typically afflicts young boys, is caused by a mutation that prevents the body from producing dystrophin, a protein crucial to the health of skeletal, respiratory and cardiac muscles. Advances in treatment for certain types of DMD-related muscle degradation have helped to prolong patients’ lifespans. However, as DMD patients age, their heart function declines dramatically.
“Patients typically live to 20 or 30 years of age,” said lead author Michelle Parvatiyar, an assistant professor in the Department of Nutrition, Food and Exercise Sciences in FSU’s College of Human Sciences. “There have been important improvements in respiratory care, which used to be what a majority of patients would succumb to. Now, in their 20s and 30s, they’re often succumbing to cardiomyopathy. The heart is functioning with a major component of the cell membrane missing. Over time, it wears out.”
The study was part of continued efforts by UCLA biologist Rachelle H. Crosbie, the study’s corresponding author, who previously identified sarcospan as a protein that could improve mechanical support in skeletal cell membranes lacking dystrophin. Her finding buoyed DMD researchers and affirmed sarcospan’s potential as an effective tool in the fight against the condition.
“But nobody had really looked at how increasing the levels of this protein might affect the heart,” Parvatiyar said.
Using a unique mouse model with a dearth of dystrophin, Parvatiyar and her collaborators did just that.
In their study, the team found that while it’s is not a like-for-like replacement for dystrophin, an overexpression of sarcospan in cardiac cells seems to do the job of stabilizing cell membranes. Even under stress, researchers found, sarcospan overexpression was able to improve the membrane defect in dystrophin-deficient cells.
“Sarcospan doesn’t quite do the job of dystrophin, but it acts as a glue to stabilize the membrane and hold protein complexes together when dystrophin is lacking,” said Parvatiyar, explaining a concept developed by Crosbie.
Cardiac measurements confirmed that sarcospan does protect the cell membrane even when the heart is placed under stress. Study co-author and FSU College of Medicine Associate Professor Jose Pinto performed the measurements, along with FSU graduate student Karissa Dieseldorff Jones and University of Miami Miller School of Medicine research assistant Rosemeire Takeuchi Kanashiro.
In addition to serving as a kind of stabilizing glue, researchers said sarcospan could also act as a scaffold that supports other essential proteins at the cell membrane. That function could allow sarcospan to carry mini versions of dystrophin — which, in its normal state, has a long and unwieldy genetic code — to the edges of cardiac cells, where they could buttress the fragile membranes.
“The idea is that you could administer the sarcospan and the dystrophin at the same time, and the sarcospan could facilitate mini dystrophin localizing to the cell membrane and help hold those complexes in place,” Parvatiyar said.
Sarcospan’s two possible functions could augment existing DMD treatments, Parvatiyar said, or they could give rise to novel therapies that fortify weakened cardiac cell membranes and improve the quality of life for people with DMD.
In her previous position at UCLA, Parvatiyar had frequent interactions with DMD patients and their families. She said these interactions, and the unshakeable hope she’s witnessed in those suffering from DMD, continue to drive her and her colleagues in the search for new ways to combat this debilitating condition.
“Those were the first times in my life I’d ever had someone come up to me and thank me for my work,” she said. “Sometimes you can feel removed from it in the laboratory day after day. You see incremental progress. But to see people who are really yearning for help is motivating. Their positivity is incredibly inspiring.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Duchenne Muscular Dystrophy Treatment Market Size 2020 Global Growth, Trends, Industry Analysis, Key Players and Forecast to 2024on August 10, 2020 at 1:58 am
Global Duchenne Muscular Dystrophy Treatment Market research report is a meticulous investigation of current scenario ...
- FDA approves Roche's Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and olderon August 9, 2020 at 10:03 pm
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 ...
- FDA Approves Genentech’s Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Olderon August 7, 2020 at 10:54 am
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam) for treatment of spinal muscular ...
- Calf sale raises money for muscular dystrophy researchon August 3, 2020 at 3:49 am
Grant has Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle degeneration and weakness. “There’s no cure for Duchenne,” Paul explains. “Boys with it don’t make it out ...
- Community rallies around parents of boys with muscular dystrophyon August 2, 2020 at 2:00 am
A community in Roscommon is rallying around a couple whose two sons suffer from a rare genetic disease, Duchenne Muscular Dystrophy (DMD.) ...
- With JETT Ride 2020, Hains brothers continue fight against Duchenne MDon August 1, 2020 at 11:19 am
Luke and Lance Hains' commitment to their younger brother, Levi Hains, and those like him who are battling Duchenne Muscular Dystrophy, remains strong.
- A Year After Gene Therapy, Boys With Muscular Dystrophy Are Healthier and Strongeron July 30, 2020 at 7:00 am
The gene therapy given to the nine boys by Pfizer was actually developed by a research team at UNC—and it took over 30 years.
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Akron Children's Hospitalon July 29, 2020 at 9:33 am
Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Akron Children's HospitalPR NewswireHACKENSACK, N., July 29, 2020Leading Duchenne Organization Expands ...
- Decatur fifth grader touches lives, keeps people laughing during coronavirus pandemicon July 28, 2020 at 4:47 pm
Ethan Lybrand, 11, is quite the jokester, at a time that we could all use a few more laughs. While he puts on a strong face with a big smile, what you can't see with Ethan is no laughing matter.
- How disabled people have been completely disregarded during the coronavirus pandemicon July 27, 2020 at 9:27 am
The lack of thought that has gone into helping people with extra needs live through the pandemic exposes ableist attitudes.
via Bing News